The Patent Finder

Visterra, Inc.

38 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 4 to 20, 2027 · next Feb 4
  • 1 fee due Apr 3, 2027
    The maintenance fee for Antibody Molecules to C5AR1 and Uses Thereof (US 11,773,179) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
  • 1 fee due May 21, 2027
    The maintenance fee for Binding Polypeptides and Methods of Making the Same (US 11,820,979) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
  • 2 fees due Jun 15 to 24, 2027 · next Jun 15
  • 1 fee due Jul 2, 2027
    The maintenance fee for Engineered polypeptides and uses thereof (US 11,858,980) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 2 fees due Aug 6 to 27, 2027 · next Aug 6
  • 1 fee due Sep 5, 2027
    The maintenance fee for Formulations of antibody molecules to dengue virus (US 11,918,651) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
  • 2 fees due Oct 2 to 30, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,877,200HA binding agents
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,096,657HA binding agents
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,969,794HA binding agents
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,024,552Ha binding agents
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,800,835HA binding agents
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,212,217Antibody Molecules to Dengue Virus and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,365,639Antibody Molecules to Dengue Virus and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,155,806Antibody Molecules to Dengue Virus and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,059,883Antibody Molecules to Dengue Virus and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 12,054,539Antibody Molecules to Dengue Virus and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 38 patents shown.
Pro members see all 38.
Pro members: see all 38 patents
Also on record, not counted in the 38: 2 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 8 abandoned · 13 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited